Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms
The invention also relates to processes for producing abuse deterrent pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.
1. A process for preparing an abuse deterrent composition, comprising formulating an abuse resistant outer polymer shell as conjugated poly(lactic-co-glycolic)-amphetamine encapsulated over an inner component as a drug-polymer matrix comprising polyanhydride-amphetamine, wherein the amphetamine comprises a regioisomeric purity >98%, less than 0.1% by weight of aziridine impurity, less than 0.3% of an organic solvent, and A less than 10 Ppm of a process-related metal, wherein the inner component is formulated as a pharmaceutically acceptable salt, solvate, prodrug, or mixture thereof, as an active pharmaceutical ingredient.
2. The process according to claim 1 , wherein the inner component and the abuse resistant outer polymer shell comprise ae multiple layers.
3. The process according to claim 2 , wherein the multiple layers comprise different drug-polymer mixtures in each layer.
4. The process according to claim 1 , wherein the abuse resistant outer polymer shell is hydrophilic and fast release, and the inner component is hydrophobic.
5. The process according to claim 1 , wherein the abuse resistant outer polymer shell comprises an additional ingredient selected from the group consisting of agar, alamic acid, alginic acid, carmellose, carboxymethylcellulose sodium, chitosan, copovidone, dextrin, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, a methylcellulose derivative, microcrystalline cellulose, polyacrylic acid, polyalkalene oxide, polyvinyl alcohol, povidone, propylene glycol alginate, a polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft co-polymer, sodium alginate, starch, and a vinylpyrrolidone-vinyl acetate copolymer.
6. The process according to claim 1 , wherein the abuse resistant outer polymer shell comprises an additional ingredient selected from the group consisting of polyethylene glycol or a derivative thereof, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylamide, polylactide, polyglycolide, polymandelic acid, polycaprolactone, polydioxan-2-one, polyamino acid, polyorthoester, polyanhydride, polycarbonate and combinations thereof.
7. The process according to claim 1 , comprising complexing the amphetamine with a compound selected from the group consisting of a peptide, a single amino acid, a dipeptide, a tripeptide, an oligopeptide, a polypeptide, a glycopeptide, a carbohydrate, a lipid, a nucleoside, a nucleic acid, a vitamin, and a combination thereof.
8. The process according to claim 1 , wherein the amphetamine is a racemic mixture of amphetamine isomers comprised of equal parts amphetamine aspartate monohydrate (25%), amphetamine sulfate (25%), dextroamphetamine saccharate (25%), and dextroamphetamine sulfate (25%).
9. The process according to claim 1 , wherein the amphetamine is a racemic mixture of amphetamine isomers comprised of equal parts amphetamine aspartate hemihydrate (25%), amphetamine sulfate (25%), dextroamphetamine saccharate (25%), and dextroamphetamine sulfate (25%).
10. The process according to claim 1 , wherein the amphetamine is (2S)-1-phenylpropan-2-amine.
11. The process according to claim 1 , wherein the inner component includes an additional ingredient selected from the group consisting of a fatty acid ester of glycerol or sorbitol, an ethoxylated sorbitan fatty acid ester, a polyethylene glycol fatty acid ester, a polyethyleneglycol ester, a polyethyleneglycol ether, a polyethoxylated carboxylic acid, vitamin E, and a PEGylated derivative of vitamin E.
12. The process according to claim 1 , comprising formulating the abuse deterrent composition in a dosage form selected from the group capsules, caplets, tablets, pills, powders, dissolving strip or tablet, a gum, wafer, cookie, aerosol, spray, solid or liquid in a gelatin capsule, granules, liquid suspension, syrup or solution.
13. The process according to claim 1 , wherein the amphetamine is selected from the group consisting of lisdexamphetamine dimesylate, and lisdexamphetamine.
14. The process according to claim 1 , comprising formulating the abuse deterrent composition as a tablet formulated to orally administer at least about 5 mg of the active pharmaceutical ingredient, or the molar equivalent amount of a salt thereof.
15. The process according to claim 1 , comprising formulating the abuse deterrent composition as a tablet formulated to orally administer between about 100 mg of the active pharmaceutical ingredient, or the molar equivalent amount of a salt thereof.
16. An abuse deterrent composition, comprising: an abuse resistant outer polymer shell comprising conjugated poly(lactic-co-glycolic)-amphetamine encapsulated over an inner component as a drug-polymer matrix comprising polyanhydride-amphetamine, wherein the amphetamine comprises a regioisomeric purity >98%, less than 0.1% by weight of aziridine impurity, less than 0.3% of an organic solvent, and less than 10 ppm of a process-related metal, wherein the inner component is formulated as a pharmaceutically acceptable salt, solvate, prodrug, or mixture thereof, as an active pharmaceutical ingredient.
17. The composition according to claim 16 , wherein the inner component and the abuse resistant outer polymer shell are multiple layers.
18. The composition according to claim 17 , wherein the multiple layers comprise different drug-polymer mixtures in each layer.